ESMO 2023大幕即将拉开,乳腺癌领域研究大放送!

作者:肿瘤瞭望   日期:2023/8/15 10:55:51  浏览量:6165

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

2023年欧洲肿瘤内科学会(ESMO 2023)年会将于当地时间10月20日~24日在西班牙马德里召开。ESMO 2023将传播最新的前沿数据,为肿瘤领域专家学者提供高质量的教育和无与伦比的交流机会。日前,官网公布了部分研究的题目和讲者信息(LBA尚未公布),《肿瘤瞭望》特将乳腺癌领域的重磅研究及中国学者将在大会壁报展示的研究进行了汇总,供读者学习和交流,如有遗漏或错误,欢迎广大读者提醒及指正。

编者按:2023年欧洲肿瘤内科学会(ESMO 2023)年会将于当地时间10月20日~24日在西班牙马德里召开。ESMO 2023将传播最新的前沿数据,为肿瘤领域专家学者提供高质量的教育和无与伦比的交流机会。日前,官网公布了部分研究的题目和讲者信息(LBA尚未公布),《肿瘤瞭望》特将乳腺癌领域的重磅研究及中国学者将在大会壁报展示的研究进行了汇总,供读者学习和交流,如有遗漏或错误,欢迎广大读者提醒及指正。
 
专场类型:Proffered Paper session
 
早期乳腺癌
日期:2023年10月20日(当地时间)
时间:14:00~15:30
地点:Bilbao Auditorium-NCC
 
5项LBA待定,目前官网暂无摘要题目和讲者信息公布
 
基础科学与转化研究(TR)
日期:2023年10月21日(当地时间)
时间:14:45~16:15
地点:Santander Auditorium-Hall 9
 
2232O-Atezolizumab(atezo)and tumour microenvironment in early triple-negative breast cancer(eTNBC):Exploratory biomarker analysis from IMpassion031
IMpassion031研究探索性生物标志物分析:阿替利珠单抗(Atezolizumab)和早期三阴性乳腺癌(eTNBC)的肿瘤微环境
讲者:Nadia Harbeck(德国,慕尼黑)
报告时间:15:25~15:35
 
晚期乳腺癌
日期:2023年10月21日(当地时间)
时间:10:15~11:45
地点:Barcelona Auditorium-Hall 9
 
376O-Trastuzumab deruxtecan(T-DXd)versus treatment of physician’s choice(TPC)in patients(pts)with HER2-low unresectable and/or metastatic breast cancer(mBC):Updated survival results of the randomized,phase 3 DESTINY-Breast04 study
随机、3期DESTINY-Breast04研究的最新生存结果:T-DXd对比医师选择治疗(TPC)在HER2低表达不可切除和/或转移性乳腺癌患者中的治疗效果
讲者:Shanu Modi(美国,纽约)
报告时间:10:25~10:35
 
377O-A Pooled Analysis of Trastuzumab Deruxtecan(T-DXd)in Patients(pts)With HER2-Positive(HER2+)Metastatic Breast Cancer(mBC)With Brain Metastases(BMs)from DESTINY-Breast(DB)-01,-02,and-03
T-DXd用于DESTINY-Breast(DB)-01、-02和-03脑转移的HER2阳性转移性乳腺癌患者的汇总分析
讲者:Sara A.Hurvitz(美国,圣莫尼卡)
报告时间:10:55~11:05
 
378O-Persistence under abemaciclib and endocrine treatment(ABA+ET)in patients with advanced breast cancer(aBC)–first results of the randomized IMPACT Trial comparing patient coaching with the MASCC Oral Agent Teaching Tool(MOATT)versus local routine patient coaching(LC).
晚期乳腺癌(aBC)患者持续接受阿贝西利联合内分泌治疗(ABA+ET)——采用MASCC口服药物患教工具(MOATT)对比当地常规患教(LC)的随机IMPACT试验首次结果。
讲者:Manfred K.Welslau(德国,阿莎芬堡)
报告时间:11:05~11:15
 
专场类型:Mini oral session
 
早期乳腺癌
日期:2023年10月23日(当地时间)
时间:16:30~18:00
地点:Bilbao Auditorium-NCC
 
238MO-Longterm residential and workplace exposure to air pollution and breast cancer risk:a case-control study nested in the French E3N cohort from 1990 to 2011
长期居住和工作场所暴露于空气污染与患乳腺癌风险:一项基于1990~2011年法国E3N队列的病例对照研究
讲者:Beatrice Fervers(Lyon,France)
报告时间:16:30~16:35
 
239MO-Impact of body mass index and its change on survival outcomes in patients with early breast cancer:a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials
BCIRG-001和BCIRG-005研究个体水平数据的汇总分析:体重指数及其变化对早期乳腺癌患者生存结局的影响
讲者:陈海珠(中国,广州)
报告时间:16:40~16:45
 
240MO-Prognostic and predictive impact of estrogen/progesterone receptor(ER/PR),and Ki-67 expression:an exploratory analysis from the monarchE trial in patients with high-risk,HR+,HER2-,early breast cancer(EBC)
monarchE研究的探索性分析:雌激素/孕激素受体(ER/PR)和Ki-67表达对高危、HR+、HER2-早期乳腺癌(EBC)患者预后和预测的影响
讲者:Matthew P.Goetz(Rochester,United States of America)
报告时间:17:00~17:05
 
241MO-Patient characteristics and real-world outcomes in HER2 negative/ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020
2008~2020年瑞典被当成三阴性乳腺癌接受治疗的HER2阴性/ER 0和ER低表达患者的特征和真实世界结局
讲者:Irma Fredriksson(Stockholm,Sweden)
报告时间:17:05~17:10
 
242MO-Association of tumor-infiltrating lymphocytes(TILs)with Recurrence Score(RS)in patients with hormone receptor-positive(HR+)/HER2-negative(HER2-)early breast cancer(BC)-a translational analysis of four prospective multicentric studies.
HR+/HER2-早期乳腺癌患者中,肿瘤浸润淋巴细胞(TILs)与复发评分(RS)的相关性——4项前瞻性多中心研究的转化分析
讲者:Federica Miglietta(Padova,Italy)
报告时间:17:10~17:15
 
243MO-Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer:three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial
浸润性乳腺癌新辅助全身治疗后豁免手术治疗:一项2期多中心前瞻性试验中预先计划的3年主要终点
讲者:Henry M.Kuerer(Houston,United States of America)
报告时间:17:40~17:45
 
244MO-A Phase II Trial Targeting Disseminated Dormant Tumor Cells with Hydroxychloroquine,Everolimus or the Combination to Prevent Recurrent Breast Cancer(“CLEVER”)
CLEVER:一项针对弥散性休眠肿瘤细胞使用羟氯喹、依维莫司或联合使用预防乳腺癌复发的Ⅱ期试验
讲者:Angela DeMichele(Philadelphia,United States of America)
报告时间:17:45~17:50
 
晚期乳腺癌
日期:2023年10月22日
时间:08:30~10:00
地点:Bilbao Auditorium-NCC
 
379MO-Datopotamab deruxtecan(Dato-DXd)+durvalumab(D)as first-line(1L)treatment for unresectable locally advanced/metastatic triple-negative breast cancer(a/mTNBC):updated results from BEGONIA,a phase 1b/2 study
Datopotamab deruxtecan(Dato-DXd)+durvalumab(D)作为不可切除的局部晚期/转移性三阴性乳腺癌(a/mTNBC)的一线治疗:Ⅰb/Ⅱ期BEGONIA研究的最新结果
讲者:Peter Schmid(英国,伦敦)
报告时间:08:30~08:35
 
380MO-SKB264(MK-2870)in previously treated hormone receptor-positive(HR+)/HER2-negative metastatic breast cancer(mBC):results from a phase I/II,single-arm,basket trial
SKB264(MK-2870)用于既往接受过治疗的激素受体阳性(HR+)/HER2-转移性乳腺癌(mBC):一项Ⅰ/Ⅱ期单臂、篮式试验的结果
讲者:殷咏梅(中国,南京)
报告时间:08:35~08:40
 
381MO-First-in-human/phase I trial of HS-20089,a B7-H4 ADC,in patients with advanced solid tumors
HS-20089(B7-H4 ADC)治疗晚期实体瘤患者的首项人体/1期试验
讲者:张剑(中国,上海)
报告时间:08:40~08:45
 
382MO-Updated results from the phase 1/2 study of OP-1250,an oral complete estrogen receptor(ER)antagonist(CERAN)and selective ER degrader(SERD)in patients(pts)with advanced or metastatic ER-positive,HER2-negative breast cancer.
口服雌激素受体(ER)拮抗剂(CERAN)及选择性ER降解剂(SERD)OP-1250用于晚期或转移性ER阳性、HER2阴性乳腺癌患者的1/2期研究的最新结果
讲者:Nancy U.Lin(美国,波士顿)
报告时间:09:00~09:05
 
383MO-Imlunestrant with or without everolimus or alpelisib,in ER+,HER2-advanced breast cancer(aBC):Results from the phase 1a/b EMBER study
1a/b期EMBER研究的结果:免疫抑制剂联合或不联合依维莫司或阿培利司治疗ER+、HER2-晚期乳腺癌
讲者:Komal Jhaveri(美国,纽约)
报告时间:09:05~09:10
 
384MO-Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy(ET)-naïve,hormone receptor-positive(HR+)advanced breast cancer(FALCON)
FALCON研究的最终总生存分析:氟维司群对比阿那曲唑治疗未经内分泌治疗的HR阳性晚期乳腺癌患者
讲者:John Robertson(英国,诺丁汉)
报告时间:09:10~09:15
 
385MO-A multicenter,open-label,dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors
DP303c在既往接受过治疗的HER2阳性晚期实体瘤患者中的多中心、开放标签、剂量递增和扩展研究
讲者:张剑(中国,上海)
报告时间:09:30~09:35
 
386MO-Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer:final results of the phase III TULIP trial
Ⅲ期TULIP试验的最终结果:Trastuzumab duocarmazine对比医师的选择治疗HER2阳性转移性乳腺癌
讲者:Philippe G.Aftimos(比利时,安德莱赫特)
报告时间:09:35~09:40
 
387MO-First Results of the SOLTI-1903 HOPE’s Patient-Centric Molecular Screening Program in Advanced Breast Cancer
SOLTI-1903 HOPE:以患者为中心的晚期乳腺癌分子筛查项目的首次结果
讲者:Tomás Pascual(西班牙,巴塞罗那)
报告时间:09:40~09:45
 
专场类型:POSTER
 
32P-Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
在HER2阳性乳腺癌曲妥珠单抗耐药形成过程中,表观遗传重编程通过过度激活的花生四烯酸代谢诱导前列腺素E2积累
讲者:殷咏梅(中国,南京)
 
47P-An Ozone Delivery System by Cisplatin Prodrug Self-assembling Micelles Combining Microwave to Sensitizing Immune Checkpoint Inhibitor in Triple-negative Breast Cancer
顺铂前体药物自组装胶束臭氧递送系统联合微波增强三阴性乳腺癌免疫检查点抑制剂的敏感性
讲者:Dan Zheng(中国,成都)
 
50P-Application and mechanism of Tarloxotinib in HER2 positive breast cancer
Tarloxotinib在HER2阳性乳腺癌中的应用及作用机制
讲者:Xinyi Shao(中国,南京)
 
51P-Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumor therapy by glutamine deprivation and cascading thrombosis
纳米工程声敏血小板对谷氨酰胺剥夺和级联血栓形成的超声动力增强乳房肿瘤治疗的协同作用
讲者:Liqiang Zhou(中国澳门)
 
167P-A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:Preliminary results from MIRACLE trial
MIRACLE试验的初步结果:基于肿瘤免疫微环境的模型用于预测绝经前激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)晚期乳腺癌患者依维莫司应用的疗效
讲者:Tan Yujing(中国,天津)
 
169P-Integration of Metabolomics and Transcriptomics to Reveal Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy in HER2+Breast Cancer Presentation Number
整合代谢组学和转录组学以揭示与HER2+乳腺癌新辅助治疗疗效相关的潜在生物标志物
讲者:张宁宁(中国,重庆)
 
170P-Clinical significance and functional role of GPR56(ADGRG1)in breast cancer
GPR56(ADGRG1)在乳腺癌中的临床意义和功能作用
讲者:陈海珠(中国,广州)
 
245P-Neoadjuvant QL1209(a pertuzumab biosimilar)compared with pertuzumab plus trastuzumab and docetaxel in early or locally advanced,HER2 positive,ER(-)/PR(-)breast cancer:a multicenter,randomized,double-blind,equivalence,phase 3 study
一项多中心、随机、双盲、等效性的Ⅲ期研究:曲妥珠单抗和多西他赛联合QL1209(帕妥珠单抗生物类似物)对比帕妥珠单抗新辅助治疗早期或局部晚期、HER2阳性、ER-/PR-乳腺癌
讲者:邵志敏(中国,上海)
 
246P-Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer:efficacy,safety and biomarker analysis from the neoALTAL trial
Ⅱ期neoALTAL研究的疗效、安全性和生物标志物分析:安罗替尼联合紫杉烷类和洛铂用于三阴性乳腺癌的新辅助治疗
讲者:齐晓伟(中国,重庆)
 
247P-KN026 in combination with docetaxel as neoadjuvant treatment for HER2+early or locally advanced breast cancer(BC):A single arm,multicenter,phase 2 study.
一项单臂、多中心、Ⅱ期研究:KN026联合多西他赛作为HER2阳性早期或局部晚期乳腺癌的新辅助治疗方案
讲者:Linxiaoxi Ma(中国,上海)
 
256P-Evolution and Risk Stratification of Adjuvant Treatment Strategies for Early Breast Cancer:A Chinese Perspective Based on National Cancer Database
基于中国国家癌症数据库的早期乳腺癌辅助治疗策略演变和风险分层
讲者:樊英(中国,北京)
 
257P-The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients:a real-world study
HER2阳性微浸润乳腺癌的特征及化疗和抗HER2治疗的必要性:一项真实世界研究
讲者:Bo Lan(中国,北京)
 
265P-Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer:a 10-year dual-center retrospective study
一项10年双中心回顾性研究:HER2低表达阳性状态对乳腺癌新辅助化疗和生存结局的影响
讲者:Yijun Li(中国,西安)
 
294P-Prognostic significance and evolution of HER2 zero,HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
新辅助治疗后HER2零表达、HER2低表达和HER2阳性乳腺癌的预后意义及发展
讲者:Dingyuan Wang(中国,北京)
 
322P-Clinicopathological Characteristics and Genomic Profiling of Pure Mucinous Breast Cancer
纯粘液性乳腺癌的临床病理特征和基因组分析
讲者:王树森(中国,广州)
 
327P-Defining≥10%radioisotope-hot stained nodes as sentinel lymph nodes by“blue dye+radioisotope”dual-tracer method for sentinel lymph node biopsy leads to the overdetection and excessive excision
前哨淋巴结活检采用“蓝色染料+放射性同位素”双示踪法将放射性同位素热染色≥10%的淋巴结定义为前哨淋巴结,会导致过度检测和过度切除
讲者:Yile Jiao(中国,成都)
 
332P-Early Prediction of Residual Cancer Burden to Neoadjuvant Chemotherapy in Breast Cancer by Longitudinal MRI-based Multitask Learning:A Multicenter Cohort Study
一项多中心队列研究:基于纵向MRI的多任务学习对乳腺癌新辅助化疗残余癌症负担的早期预测
讲者:Wei Li(中国,北京)
 
336P-Dual-mode near-infrared multispectral imaging system equipped with deep learning models improves the identification of cancer foci in breast cancer specimens
基于深度学习模型的双模式近红外多光谱成像系统提高了乳腺癌标本中病灶的识别
讲者:刘月平(中国,石家庄)
 
360P-Neoadjuvant Inetetamab Combined with Pertuzumab,Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer:Primary Analysis of a Phase II Study.
一项Ⅱ期研究的初步分析:Inetetamab联合帕妥珠单抗、紫杉醇和卡铂新辅助治疗局部晚期HER2阳性乳腺癌
讲者:Yue Chai(中国,北京)
 
361P-A phase 2 study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2-locally advanced breast cancer
氟维司群联合化疗用于HR+/HER2-局部晚期乳腺癌新辅助治疗的Ⅱ期临床研究
讲者:Jing Wu(中国,重庆)
 
397P-Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing,locally advanced or metastatic breast cancer:a single-arm phase II study
重组人源化抗HER2单克隆抗体-MMAE偶联物RC48-ADC治疗HER2阳性或HER2低表达、局部晚期或转移性乳腺癌患者的疗效和安全性:一项单臂Ⅱ期研究
讲者:Fei Qu(中国,南京)
 
398P-A phase Ib/II study of IN10018/FAKi in combination with pegylated liposomal doxorubicin(PLD)and Toripalimab in metastatic triple-negative breast cancer(TNBC):IN10018-010
IN10018/FAKi联合聚乙二醇脂质体多柔比星(PLD)和特瑞普利单抗治疗转移性三阴性乳腺癌的Ⅰb/Ⅱ期研究:IN10018-010
讲者:胡夕春(中国,上海)
 
399P-Results from a first-in-human Phase Ia/b study of LX-039,an oral selective estrogen receptor(ER)degrader(SERD),in postmenopausal patients with ER+,HER2-advanced breast cancer(ABC)
口服选择性雌激素受体降解剂LX-039治疗绝经后ER+、HER2-晚期乳腺癌(ABC)患者的首次人类Ⅰa/b期研究结果
讲者:Weina Shen(中国,上海)
 
401P-Utidelone in combination with etoposide and bevacizumab in HER2 negative breast cancer with brain metastasis(UTOBIA-BM):a prospective,single-arm,phase II trial
优替德隆合依托泊苷和贝伐珠单抗治疗HER2阴性乳腺癌脑转移(UTOBIA-BM)患者:一项前瞻性、单臂、Ⅱ期试验
讲者:史业辉(中国,天津)
 
404P-A multicenter,single-arm,open-label trial of Birociclib,a CDK4/6 inhibitor,as a single agent,in patients with refractory HR+/HER2-metastatic breast cancer
CDK4/6抑制剂Birociclib单药治疗难治性HR+/HER2-转移性乳腺癌的多中心、单臂、开放标签试验
讲者:王佳玉(中国,北京)
 
408P-Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+metastatic breast cancer:a phase I study
一项Ⅰ期研究:Proxalutamide联合内分泌治疗用于HR+/HER2-/AR+转移性女性乳腺癌患者
讲者:李惠平(中国,北京)
 
418P-Two-year follow-up data on the efficacy and safety of KN026,a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer.
HER2靶向双特异性抗体KN026联合多西他赛一线治疗HER2阳性复发/转移性乳腺癌的2年随访数据。
讲者:张清媛(中国,哈尔滨)
 
423P-A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer
以阿帕替尼为基础的方案在转移性三阴性乳腺癌中临床价值的真实世界研究
讲者:Huang W.Wei(中国,福州)
 
424P-Pyrotinib plus capecitabine for trastuzumab-resistant,HER2-positive advanced breast cancer:updated survival results from the phase 2 PICTURE trial
2期PICTURE试验的最新生存结果:吡咯替尼联合卡培他滨治疗曲妥珠单抗耐药的HER2阳性晚期乳腺癌
讲者:胡夕春(中国,上海)
 
426P-The overall survival data of FUTURE-C-PLUS:combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced,immunomodulatory triple-negative breast cancer,an open-label,single-arm,phase 2 trial
开放标签的、单臂、2期试验FUTURE-C-PLUS研究:法米替尼+卡瑞利珠单抗+白蛋白结合型紫杉醇作为晚期免疫调节型三阴性乳腺癌一线治疗的总生存数据
讲者:王中华(中国,上海)
 
427P-Pyrotinib Plus Trastuzumab versus Pertuzumab Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer:A Multicenter,Retrospective Study
一项多中心、回顾性研究:吡咯替尼联合曲妥珠单抗对比帕妥珠单抗联合曲妥珠单抗治疗HER2阳性转移性乳腺癌
讲者:王碧芸(中国,上海)
 
433P-Effectiveness and safety of vinorelbine+inetetamab+pyrotinib in≥second-line treatment of HER2-positive metastatic breast cancer
长春瑞滨+伊尼妥单抗+吡咯替尼作为二线及后线方案治疗HER2阳性转移性乳腺癌的有效性和安全性
讲者:Wu Fan(中国,福州)
 
436P-Preliminary results from a prospective study of inetetamab in combination with pyrotinib and utidelone for HER2-positive metastatic breast cancer(IPUtrial)
伊尼妥单抗联合吡咯替尼和优替德隆治疗HER2阳性转移性乳腺癌的前瞻性研究(IPUtrial)的初步结果
讲者:Hui Cao(中国,沈阳)
 
438P-Phase 1 study of ZV0203,a first in class pertuzumab ADC,in patients with HER2+advanced solid tumors
ZV0203(一类首创帕妥珠单抗ADC类药物)在HER2+晚期实体瘤患者中的1期研究
讲者:Yunsheng Huang(中国,杭州)
 
445P-Tyrosine kinase inhibitors(TKIs)in HER2-positive metastatic breast cancer after trastuzumab emtansine(T-DM1)failure:A multicenter real-world study
一项多中心真实世界研究:酪氨酸激酶抑制剂(TKIs)用于T-DM1治疗失败后的HER2阳性转移性乳腺癌
讲者:Chunxiao Sun(中国,南京)
 
447P-Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer:a systematic review and meta-analysis
一项系统综述和荟萃分析:曲妥珠单抗联合或不联合酪氨酸激酶抑制剂治疗HER2阳性乳腺癌的疗效和安全性
讲者:Lixi Li(中国,北京)
 
450P-A prospective,single-arm,single-center,exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
安罗替尼联合伊立替康治疗二线及以上HER2-晚期乳腺癌的前瞻性、单臂、单中心、探索性临床研究
讲者:Ying Zhang(中国,无锡)
 
452P-A Phase II Trial of Anlotinib and Fulvestrant in Patients with Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
安罗替尼联合氟维司群治疗既往经芳香化酶抑制剂治疗的转移性乳腺癌患者
讲者:王晓稼(中国,杭州)
 
453P-Clinical outcomes of Pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer
既往经曲妥珠单抗和帕妥珠单抗治疗的HER2阳性转移性乳腺癌接受以吡咯替尼为基础的治疗的临床结局
讲者:周金妹(中国,北京)
 
464P-Developing a Prognostic Risk Stratification Model and Treatment Options for HER2-Positive Breast Cancer Brain Metastasis
开发HER2阳性乳腺癌脑转移的预后风险分层模型和治疗方案
讲者:JiaXin Chen(中国,北京)
 
466P-Integrated analysis of potential prognosis and differential expression between primary and metastatic foci for COL12A1 in breast cancer
乳腺癌原发灶和转移灶中COL12A1的潜在预后和差异表达的综合分析
讲者:Lei Tang(中国,苏州)
 
488P-Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population
全面的基因组分析以确定中国人群中乳腺癌脑转移的可操作改变
讲者:Qianyi Lu(中国,广州)
 
492P-Wound stress stimulation promotes lung metastasis of breast cancer by regulating CXCL12/CXCR4 axis through MDSC exosome miR-126a-5p
伤口应力刺激通过MDSC外泌体miR-126a-5p调控CXCL12/CXCR4轴促进乳腺癌肺转移
讲者:Xiaomeng Yin(中国,成都)
 
496P-Comprehensive Genomic Profiling of Advanced HR+/HER2-Breast Cancer Patients Using Liquid Biopsy
利用液体活检对晚期HR+/HER2-乳腺癌患者进行全面的基因组分析
讲者:邵彬(中国,北京)
 
686P-Phase 1 study of HRS8807,an oral selective ER covalent antagonist(SERCA),in ER+/HER2-locally advanced(LA)or metastatic(M)breast cancer(BC)
口服选择性ER共价拮抗剂(SERCA)HRS8807治疗ER+/HER2-局部晚期或转移性乳腺癌的1期研究
讲者:吴炅(中国,上海)

版面编辑:张靖璇  责任编辑:卢宇

本内容仅供医学专业人士参考


乳腺癌

分享到: 更多